Veracyte to replace Triumph in S&P SmallCap 600 index
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 25 2025
0mins
Source: SeekingAlpha
Veracyte's Index Replacement: Biotechnology company Veracyte (VCYT) will replace Triumph Group (TGI) in the S&P SmallCap 600 index on July 29, following Triumph's acquisition by private equity firms for approximately $3 billion.
Stock Performance and Projections: Veracyte shares rose by 6.49% to $25.12 pre-market, with the company projecting significant growth in its Decipher and Afirma products and targeting a 22.5% adjusted EBITDA margin for 2025.
Analyst Views on VCYT
Wall Street analysts forecast VCYT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCYT is 42.17 USD with a low forecast of 28.00 USD and a high forecast of 48.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 41.000
Low
28.00
Averages
42.17
High
48.00
Current: 41.000
Low
28.00
Averages
42.17
High
48.00
About VCYT
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
